SPRO
Spero Therapeutics Inc

2,739
Mkt Cap
$145.36M
Volume
200,360.00
52W High
$3.22
52W Low
$0.5052
PE Ratio
-3.25
SPRO Fundamentals
Price
$2.58
Prev Close
$2.59
Open
$2.58
50D MA
$2.36
Beta
0.86
Avg. Volume
382,304.98
EPS (Annual)
-$1.27
P/B
5.48
Rev/Employee
$856,125.00
$7.07
Loading...
Loading...
News
all
press releases
Short Interest in Spero Therapeutics, Inc. (NASDAQ:SPRO) Declines By 24.0%
Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) was the recipient of a large decline in short interest during the month of February. As of February 13th, there was short interest totaling...
MarketBeat·12d ago
News Placeholder
More News
News Placeholder
Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above 200-Day Moving Average - Should You Sell?
Spero Therapeutics (NASDAQ:SPRO) Shares Cross Above 200 Day Moving Average - Should You Sell...
MarketBeat·17d ago
News Placeholder
Esther Rajavelu Sells 87,917 Shares of Spero Therapeutics (NASDAQ:SPRO) Stock
Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) insider Esther Rajavelu sold 87,917 shares of the firm's stock in a transaction dated Friday, February 6th. The shares were sold at an average...
MarketBeat·1mo ago
News Placeholder
Insider Selling: Spero Therapeutics (NASDAQ:SPRO) Insider Sells 18,442 Shares of Stock
Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) insider Esther Rajavelu sold 18,442 shares of the company's stock in a transaction on Monday, February 2nd. The shares were sold at an average...
MarketBeat·1mo ago
News Placeholder
Spero Therapeutics (NASDAQ:SPRO) Insider Sells 18,442 Shares
Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) insider Esther Rajavelu sold 18,442 shares of the business's stock in a transaction dated Monday, February 2nd. The stock was sold at an...
MarketBeat·1mo ago
News Placeholder
Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200 Day Moving Average - What's Next?
Spero Therapeutics (NASDAQ:SPRO) Stock Passes Below 200-Day Moving Average - Time to Sell...
MarketBeat·1mo ago
News Placeholder
GSK's Q4 Earnings & Sales Beat Estimates, Stock Up on '26 Outlook
GSK's Q4 earnings and sales top estimates as strong specialty medicine demand fuels growth and drives shares higher on an upbeat 2026 outlook.
Zacks·1mo ago
News Placeholder
Spero Therapeutics (NASDAQ:SPRO) Raised to "Buy" at Wall Street Zen
Wall Street Zen upgraded shares of Spero Therapeutics from a "hold" rating to a "buy" rating in a report on Sunday...
MarketBeat·2mo ago
News Placeholder
Spero Therapeutics (NASDAQ:SPRO) Downgraded by Wall Street Zen to Hold
Wall Street Zen downgraded shares of Spero Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday...
MarketBeat·2mo ago
News Placeholder
Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200-Day Moving Average - Here's What Happened
Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200 Day Moving Average - Here's What Happened...
MarketBeat·2mo ago
<
1
2
...
>

Latest SPRO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.